期刊文献+

ROS1基因在非小细胞肺癌靶向治疗中的研究进展 被引量:3

Research progress in ROS1 gene in non-small cell lung cancer
下载PDF
导出
摘要 肺癌是最常见的恶性肿瘤之一,ROS1基因是新近发现的出现在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的原癌基因,它编码的蛋白是受体络氨酸激酶超家族成员之一,是一种对细胞生长和生存起着重要作用的蛋白。越来越多的研究表明,ROS1基因的改变是NSCLC个体化治疗的一个新的分子靶点。本文将重点综述ROS1的重排在NSCLC的特点、ROS1基因重排的检测方法,以及NSCLC中以ROS1重排基因作为药物靶点的研究进展。 Lung cancer is one of the most common malignant cancers. ROS1 is an oncogene which is newly found in non-small cell lung cancer(NSCLC). The protein encoded by ROS1 is a member of receptor tyrosine kinase superfamily, and it plays a vital role in cell growth and cell survival. More and more studies demonstrated that the alteration of ROS1 would be a new molecular target for individualized treatment of NSCLC. This review focus on the feature of ROS1 rearrangements in NSCLC, the detection methods of ROS1 rearrangement, and the research progress about taking ROS1 rearrangement as drug target in NSCLC
出处 《临床与病理杂志》 2014年第6期825-830,共6页 Journal of Clinical and Pathological Research
关键词 ROS1融合基因 非小细胞肺癌 分子靶向治疗 克唑替尼 ROS1 non-small-cell lung cancer targeted therapy crizotinib
  • 相关文献

参考文献2

二级参考文献24

  • 1Dimou A, Harrington K, Syrigos KN. From the bench to bedside:biological and methodology considerations for the future of companiondiagnostics in non-small cell lung cancer. Patholog Res Int, 2011, 2011:312346.
  • 2Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment ofEML4-ALK non-small cell lung cancer. EurJ Cancer, 2010,46(10):1773-1780.
  • 3Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapyfor non-small cell lung cancer with mutated EGFR. N Engl J Med, 2010,362(25):2380-2388.
  • 4Ciardiello F, Jezdic S. New insights on personalized cancer treatment:A report from the ESMO congress. Expert Rev Anticancer Ther, 2011,11(1):21-23.
  • 5Soda M, Choi YL, Enomoto M, et al. Identification of the transformingEML4-ALK fusion gene in non-small cell lung cancer. Nature, 2007,448(7153):561-566.
  • 6Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements definea unique molecular class of lung cancers. J Clin Oncol, 2012, 30(8):863-870.
  • 7Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinaseinhibition in non-small-cell lung cancer. N Engl J Med, 2010, 363(18):1693-1703.
  • 8Gaughan EM, Costa DB. Genotype-driven therapies for non-small-cell-lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. TherAdvMed Oncol, 2011, 3(3): 113-125.
  • 9Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lungcancer. Clin. Cancer Res, 2011,17(8): 2081-2086.
  • 10Weickhardt AJ, Camidge DR. The therapeutic potential of anaplasticlymphoma kinase inhibitors in lung cancer: rationale and clinicalevidence. Clin Invest, 2011,1(8): 1119-1126.

共引文献20

同被引文献15

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部